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Background: Comorbidity is a predictor of postoperative complications (PCs) in gastrectomy. However, it remains
unclear which comorbidities are predictors of PCs in patients who undergo laparoscopy-assisted gastrectomy (LAG).
Clinically, insufficient lymphadenectomy (LND) is sometimes performed in high-risk patients, although the impact
on PCs and outcomes remains unclear.
Methods: We retrospectively studied 529 patients with gastric cancer (GC) who underwent LAG. PCs were defined
as grade 2 or higher events according to the Clavien-Dindo classification. We evaluated various comorbidities as risk
factors for PCs and examined the impact of insufficient LND on PCs in patients with risky comorbidities.
Result: A total of 87 (16.4%) patients had PCs. There was no PC-related death. On univariate analysis, heart disease,
central nervous system (CNS) disease, liver disease, renal dysfunction, and restrictive pulmonary dysfunction were
significantly associated with PCs. Both liver disease and heart disease were significant independent risk factors for
PCs on multivariate analysis (odds ratio [OR] = 3.25, p = 0.022; OR = 2.36, p = 0.017, respectively). In patients with
one or more risky comorbidity, insufficient LND did not significantly decrease PCs (p = 0.42) or shorten GC-specific
survival (p = 0.25).
Conclusion: In patients who undergo LAG for GC, the presence of heart disease or liver disease is an independent
risk factor for PC. Insufficient LND (for example, D1+ for advanced GC) might be permissible in high-risk patients,
because although it did not reduce PCs, it had no negative impact on GC-specific survival.Background
Gastric cancer (GC) is the fourth most common malig-
nancy [1]. At present, the worldwide treatment of choice
for GC is complete surgical removal of the tumor and
adjacent lymph nodes. Surgical outcomes are influenced
by various factors, including patients’ characteristics and
concurrent disease, type of operation, and quality of
care. Postoperative complications (PCs) negatively affect
the quality of life of patients who undergo gastrectomy
and can even be life-threatening. Identification of risk
factors for PCs might help to reduce such complications,
and many studies have attempted to evaluate risk factors
for PCs associated with various procedures. Comorbidity
has been reported to be a predictor of PCs in patients* Correspondence: m-inokuchi.srg2@tmd.ac.jp
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unless otherwise stated.who receive gastrectomy for GC [2-5]. However, what
types of comorbidities are associated with the highest risk
of PCs in patients who undergo gastrectomy remains to
be fully defined. Risk factors probably differ between
abdominal (surgical) and non-abdominal (medical) PCs.
The primary objective of study was to clarify comorbidi-
ties associated with PCs in laparoscopy-assisted gastrec-
tomy (LAG), a procedure for less invasive surgery
increasingly used throughout the world. Clarifying specific
comorbidities might contribute to improved treatment
strategies for GC.
Scoring systems such as the Estimation of Physiologic
Ability and Surgical Stress (E-PASS) score and the Physio-
logic and Operative Severity Score for the enUmeration
of Mortality and morbidity (POSSUM) are useful for
predicting the risks of mortality and morbidity after
various operations [6,7], although they are not commonly
used in clinical practice. In patients with comorbiditiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dardized treatments, such as gastrectomy with D2 lymph-
adenectomy (LND) for advanced GC, tend to be avoided
by surgeons. However, criteria for the selection of patients
who should undergo insufficient LND and the impacts of
insufficient LND on PCs and survival in high-risk patients
remain to be defined. The secondary objective of this
study was to evaluate the outcomes of high-risk patients
who underwent insufficient LND. We verified whether
insufficient LND negatively affects postoperative survival
in this retrospective study.
Methods
We retrospectively identified 529 consecutive patients
who underwent LAG with LND for pathological stage I
to III GC in our hospital between 2003 and 2012. Patients
who underwent thoracolaparotomy, emergency surgery,
incomplete tumor resection, and combined operations for
other malignancies were excluded. The present study was
in compliance with the Declaration of Helsinki, and was
approved by the ethics committee of Tokyo Medical and
Dental University. In principle, early-stage GC was treated
by LAG in accordance with the treatment guidelines of
the Japanese Gastric Cancer Association [8]. The extent of
LND was retrospectively classified as D1, D1+ (α or β), or
D2 in accordance with the treatment guidelines, version 2
[8]. However, reduced LND was performed in patients
with severe comorbidities. In patients who underwent
LAG, carbon dioxide pneumoperitoneum was maintained
at 10 mm Hg, and a 4- to 5-cm incision was made in the
upper abdomen or navel to remove tissue specimens and
conduct anastomosis. For lymph node dissection, we used
harmonic scissors and monopolar and bipolar electric
cautery devices. All patients received systemic antibiotics
(a first-generation cephem) several times on the day of
surgery. The nasogastric tube was left in place until post-
operative day 1 according to our protocol.
All patients preoperatively underwent venous blood
analysis (including hemoglobin, serum albumin, and
creatinine), electrocardiography, chest radiography, and
pulmonary function testing, including vital capacity
(VC), forced expiratory volume in 1 second (FEV1), and
forced vital capacity (FVC). The results of these examina-
tions were retrieved from the patients’ electronic medical
records. The following variables were obtained from our
prospective GC database: patient age and gender; body
mass index (BMI); comorbidities; regular use of steroids;
tumor characteristics; extent of lymph-node dissection;
operation time; estimated blood loss; and PCs. All comor-
bidities other than pulmonary and renal dysfunction
were defined as conditions that required treatment. For
example, heart disease included ischemic disease treated
by interventional procedures, atrial fibrillation requiring
anticoagulant treatment, and congenital cardiac failuretreated by medication. Liver disease included both cirrhosis
and chronic hepatitis treated by medication. Pulmonary
dysfunction was classified into two categories on basis of
the results of preoperative spirometry. Restrictive pulmon-
ary dysfunction was defined as a predicted VC of less than
80%, and chronic obstructive pulmonary disease (COPD)
was defined as an FEV1/FVC ratio of less than 0.70. Renal
dysfunction was defined as a serum creatinine concentra-
tion higher than the upper limit of normal according to our
hospital’s criteria (>1.1 mg/dL in males and >0.8 mg/dL in
females). Anemia was defined according to the World
Health Organization (WHO) criteria (<13 g/dL in males
and <12 g/dL in females). Hypoalbuminemia was defined
as a serum albumin concentration of less than 3.5 g/dL.
In addition, some comorbidities were classified into two
groups according to severity.
All patients were followed up until June 2013. The
median follow-up was 52 months (5.5-126). A total of 59
(11.1%) patients died, 19 (3.6%) had recurrence of GC,
and 40 (7.6%) died of other causes. Thirty-two patients
(6.0%) died of benign diseases, such as cardiac, pulmon-
ary, hepatic, and renal disease.
Patients’ characteristics and surgical outcomes are
shown in Table 1. In this study, PCs were defined as grade
2 or higher events according to the Clavien-Dindo classifi-
cation that occurred within 30 days after gastrectomy [9].
In addition, PCs were classified into either abdominal or
non-abdominal complications.
Next, we identified patients who had comorbidities that
were risk factor for PCs. They were divided into two
groups: patients underwent insufficient LND and those
underwent sufficient LND. Insufficient LND included
both insufficient D1+ dissection in pathological stage
IA cancer with submucosal invasion and insufficient D2
dissection in pathological stage IB or more advanced
cancer. We compared clinical outcomes between the
patients who underwent insufficient LND and those
underwent sufficient LND.
Statistical analysis
All variables were classified into two categories and were
compared with the use of the chi-square test or Fisher’s
exact test, as appropriate. Multivariate analysis was carried
out by binary logistic multiple regression testing using
dummy variables. Seven patients (1.3%) were excluded from
the multivariate analysis because of missing data. Survival
was measured from the date of performing LAG to the
latest follow-up date or the date of death. Kaplan-Meier
curves were plotted to assess the effect of insufficient LND
for patients with any risky comorbidity on survival. Differ-
ent curves of survival were compared using the log-rank
test. P values of <0.05 were considered to indicate statistical
significance. All analyses were performed with the statistical
software package SPSS 20 (SPSS Japan Inc., Tokyo, Japan).





Age mean ± SD 64.9 ± 11.5
Body mass index (kg/m2) mean ± SD 22.9 ± 3.1
Comorbidities 326 (61.6)
Heart disease 50 (9.5)
Ischemic disease 24 (4.5)
Arrhythmia 24 (4.5)
Congenital cardiac failure 3 (0.6)
Others 7 (1.3)
CNS disease 39 (7.4)
Cerebrovascular disease 30 (5.7)
Neurodegenerative disease 6 (1.1)
Others 3 (0.6)
Liver disease 21 (4.0)
Liver cirrhosis 8 (1.5)
Chronic hepatitis 13 (2.4)
Renal dysfunctiona) 54 (10.2)
Pulmonary dysfunction 124 (23.4)
Restrictive pulmonary dysfunctionb) 25 (4.7)
COPD 112 (21.2)
Diabetes mellitus 67 (12.7)
Hypertension 184 (34.8)











Combined resection 54 (10.2)
Gallbladder 39 (7.4)
Spleen 13 (2.5)
Intestine or colon 2 (0.4)
Operating time (min) mean ± SD 287 ± 75
Bleeding (g) median (range) 72 (0 – 2492)






SD standard deviation, CNS central nervous system.
COPD: chronic obstructive pulmonary disease, LND: lymph node dissection
a)serum creatinine concentration higher than the upper limit of normal at our
hospital, >1.10 in males and >0.80 in females.
b)predicted vital capacity <80%.
c)decreased hemoglobin, <13 g/dL in males and <12 g/dL in females.
d)decreased serum albumin <3.5 g/dL.
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A total of 87 (16.4%) patients had PCs. There was no
PC-related death. Overall, 66 (12.5%) patients had abdom-
inal complications, 5 (0.9%) had cardiac complications, 10
(1.9%) had pulmonary complications, and 15 (2.8%) had
other complications. The details of the PCs are shown in
Table 2. As for surgical factors, D2 LND, D1+ LND, and
D1 LND were performed in 77 (14.6%), 448 (84.7%), and 4
(0.8%) patients, respectively. Total gastrectomy, proximal
gastrectomy, and distal gastrectomy were performed in 78
(14.7%), 34 (6.4%), and 417 (78.8%) patients.
All PCs
On univariate analysis, PCs were significantly associated
with many factors: male gender, higher age (≥75 years),
heart disease, CNS disease, liver disease, renal dysfunction,
restrictive pulmonary dysfunction, anemia, regular use
of steroids, total gastrectomy, combined resection of
other organ (except gallbladder), extended operating time
(≥300 minutes), and higher operative bleeding volume
(≥300 g) (Table 3). Only 5 patients (0.9%) received transfu-
sion, and transfusion was not assessed in this study. Next,
we evaluated independent risk factors for PCs using a
multivariate model adjusted for all of the above risk
factors (Table 4). Finally, both liver disease and heart
disease were independent risk factors significantly related
to PCs on multivariate analysis (odds ratio [OR] = 3.25,
95% confidential interval [CI]: 1.18-8.91, p = 0.022;
OR = 2.36, 95% CI: 1.17-4.76, p = 0.017, respectively).
The following factors showed a trend toward being risk
factors on multivariate analysis: CNS disease (OR = 2.24,
95% CI: 1.00-5.01, p = 0.050), renal dysfunction (OR = 2.01,
95% CI: 0.98-4.13, p = 0.058), male gender (OR = 1.75, 95%
CI: 0.93-3.29, p = 0.082), higher age (OR = 1.70, 95% CI:
0.95-3.03, p = 0.075), combined resection (OR = 2.85, 95%
CI: 0.88-9.27, p = 0.081), and extended operating time
(OR = 1.61, 95% CI: 0.95-2.73, p = 0.079).
Subcategorized PCs
For analysis, PCs were subcategorized into abdominal and
non-abdominal (cardiac, pulmonary, etc.) PCs. Abdominal
Table 2 Postoperative complications
n % Grade 2/3/4/5
Total 87 (16.4) 48/34/5/0
Abdominal 66 (12.5) 31/33/2/0
Anastomotic leakage 8 (1.5) 0/7/1/0
Pancreatic fistula 5 (0.9) 1/4/0/0
Abdominal abscess 14 (2.6) 4/10/0/0
Anastomotic stenosis 14 (2.6) 3/11/0/0
Ileus 9 (1.7) 5/3/1/0
Gastric stasis 5 (0.9) 5/0/0/0
Postoperative bleeding 4 (0.8) 3/1/0/0
Ascites 4 (0.8) 3/1/0/0
Cholecystitis 2 (0.4) 1/1/0/0
Cholerrhagia 1 (0.2) 0/1/0/0
Reflux esophagitis 2 (0.4) 2/0/0/0
Enteritis 1 (0.2) 1/0/0/0
Wound infection 6 (1.1) 6/0/0/0
Non-abdominal 30 (0.9) 25/2/3/0
Ischemic attack 1 (0.2) 0/0/1/0
Arrhythmia 4 (0.8) 4/0/0/0
Pneumonia 6 (1.1) 5/1/0/0
ARDS 2 (0.4) 0/0/2/0
Atelectasis 2 (0.4) 2/0/0/0
Urinary tract infection 2 (0.4) 2/0/0/0
Infection of venous catheter 1 (0.2) 1/0/0/0
Deep vein thrombosis 1 (0.2) 0/1/0/0
Cerebral bleeding 1 (0.2) 0/0/1/0
Delirium 12 (2.3) 12/0/0/0
ARDS acute respiratory distress syndrome.
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inal PCs were significantly associated with many factors
on univariate analysis (Table 3). Multivariate analysis
showed 3 independent predictors of abdominal PCs: liver
disease (OR = 3.10, 95% CI: 1.13-8.47, p = 0.028), heart
disease (OR = 2.40, 95% CI: 1.20-4.82, p = 0.013), and renal
dysfunction (OR = 2.13, 95% CI: 1.06-4.29, p = 0.035).
Extended operating time and higher operative bleeding
were not significant predictors on multivariate analysis
(OR = 1.57, 95% CI: 0.93-2.64, p = 0.093; OR = 1.22, 95%
CI: 0.54-2.76, p = 0.64, respectively) (Table 4).
Non-abdominal PCs were also significantly associated
with many factors on univariate analysis (Table 3). Heart
disease was also an independent risk factor for non-
abdominal PCs (OR = 2.31, 95% CI: 1.15-4.64, p = 0.019)
on multivariate analysis. Three other factors were inde-
pendent predictors of non-abdominal PCs: higher age
(OR = 1.84, 95% CI: 1.04-3.26, p = 0.036), regular use of
steroids (OR = 4.47, 95% CI: 1.04-19.3, p = 0.045), andextended operating time (OR = 1.71, 95% CI: 1.02-2.86,
p = 0.043) (Table 4).
Relation between PCs and severity of comorbidities
The severity of each comorbidity was not significantly
related to an increased incidence of PCs, although a high
rate of PCs was found in patients with liver cirrhosis
(Table 5).
Impact of insufficient LND on PCs and survival of patients
with any risky comorbidity
We assessed the impact of insufficient LND (as defined
in the Methods section) on PCs and survival in patients
with the following risky comorbidities: heart disease, CNS
disease, liver disease, renal dysfunction, and restrictive
pulmonary dysfunction, all of which were significantly
associated with PCs. A total of 149 patients (28% of all
patients) had these risky comorbidities, and 42 (28%) of
these patients underwent insufficient LND. The character-
istics of the patients included in this portion of the study
are shown in Table 6. The patients who underwent insuffi-
cient LND had a more advanced stage of GC (p < 0.001).
The incidences of all PCs and of abdominal PCs were
similar in the patients who underwent insufficient LND
and those who underwent sufficient LND (29% vs 30%,
p = 0.87; 19% vs 25%, p = 0.42, respectively). However,
the incidence of non-abdominal PCs was significantly
higher in the patients who underwent insufficient LND
than in those who underwent sufficient LND (21% vs
8%, p = 0.028) (Table 6). The overall survival rate was
slightly, but not significantly lower in patients who
received insufficient LND (60.6% vs 79.0%, p = 0.24).
However, GC-specific survival was similar in the two
groups (90.6% vs 94.4%, p = 0.25), regardless of the fact
that patients who underwent insufficient LND had a
significantly more advanced stage of GC than those who
underwent sufficient LND (Table 7).
Discussion
Our results showed that heart, CNS, liver, renal, and
pulmonary comorbidities or dysfunctions were risk fac-
tors for PCs after radical gastrectomy. Heart disease and
liver disease were independent risk factors for PCs in the
present study, consistent with the results of a previous
study of gastrectomy with D2 LND by Jeong et al. [2].
Heart disease and liver disease might be common risk
factors after gastrectomy. However, Jeong et al. did not
mention renal or pulmonary dysfunction, and the rates of
comorbidities such as heart disease (4.6%) and neuro-
logical disease (2.2%) were lower than those in our study.
Moreover, the rate of laparoscopic surgery was only 9.0%
in their study. Another study found that liver cirrhosis
and hypertension were independent risk factors for PCs in
patients ≥70 years of age who underwent gastrectomy [5].
Table 3 Univariate analysis for risk factors of PCs in LAG
All Abdominal Non-abdominal
n n (%) p n (%) p n (%) p
Gender male 380 71 (18.7) 0.027 53 (13.9) 0.10 27 (7.1) 0.023
female 149 16 (10.7) 13 (10.8) 3 (2.0)
Age ≥75 117 34(29.0) <0.001 27 (23.1) <0.001 12 (11.4) 0.015
<75 412 53 (12.9) 39 (9.5) 18 (4.4)
Body mass index ≥25 (kg/m2) 136 18 (13.2) 0.24 15 (11.0) 0.55 6 (4.4) 0.46
<25 393 69 (17.6) 51 (13.0) 24 (6.1)
Heart disease yes 50 18 (36.0) <0.001 13 (26.0) 0.002 10 (20.0) <0.001
no 479 69 (14.4) 53 (11.1) 20 (4.1)
CNS disease yes 39 13 (33.3) 0.003 10 (25.6) 0.020 7 (17.9) 0.004
no 490 74 (15.1) 56 (11.4) 23 (4.7)
Liver disease yes 21 8 (38.1) 0.013 8 (38.1 <0.001 2 (9.5) 0.34
no 508 79 (15.6) 58 (11.4) 28 (5.5)
Diabetes mellitus yes 67 12 (17.9) 0.73 10 (14.9) 0.52 5 (7.5) 0.57
no 462 75 (16.2) 56 (12.1) 25 (5.4)
Hypertension yes 184 34 (18.5) 0.36 25 (13.6 0.57 13 (7.1) 0.31
no 345 53 (15.4) 41 (11.9) 17 (4.9)
Renal dysfunction yes 54 17 (31.5) 0.002 14 (25.9) 0.002 6 (11.1) 0.11
no 475 70 (14.7) 52 (12.3) 24 (5.1)
Restrictive pulmonary dysfunction yes 25 10 (40.0) 0.003 7 (28.0) 0.026 6 (24.0) 0.001
no 498 75 (15.0) 58 (13.2) 23 (4.6)
not evaluated 6 2 1 1
COPD yes 112 17 (15.2) 0.73 11 (9.8) 0.35 8 (7.1) 0.41
no 411 68 (16.5) 54 (13.1) 21 (5.1)
not evaluated 6 2 1 1
Anemia yes 131 29 (22.1) 0.043 22 (16.8) 0.085 12 (9.2) 0.047
no 398 58 (14.6) 44 (11.1) 18 (4.5)
Hypoalbuminemia yes 8 3 (37.5) 0.13 2 (25.0) 0.26 2 (25.0) 0.071
no 519 84 (16.2) 64 (12.3) 28 (5.4)
not evaluated 2 0 0 0
Regular use of steroid yes 9 4 (44.4) 0.045 2 (22.2) 0.31 2 (22.2) 0.087
no 520 83 (16.0) 64 (12.3) 28 (5.4)
Type of resection total or proximal 112 29 (25.9) 0.002 20 (17.9) 0.052 13 (11.6) 0.002
distal 417 58 (13.9) 46 (12.4) 17(4.1)
Extent of lymph node dissection D2 77 15 (19.5) 0.44 10 (13.0) 0.88 5 (6.5) 0.79
D1+ or D1 452 72 (15.9) 56 (12.4) 25 (5.5)
Combined resection yes 16 6 (37.5) 0.033 4 (25.0) 0.13 2 (12.5) 0.23
no or gallbladder 513 81 (15.8) 62 (12.1) 28 (5.5)
Operating time ≥300 (min) 253 52 (20.6) 0.015 39 (15.4) 0.050 19 (7.5) 0.080
<300 276 35 (12.7) 27 (9.8) 11 (4.0)
Estimated bleeding ≥500(g) 43 12 (27.9) 0.031 10 (23.3) 0.026 4 (9.3) 0.28
<500 485 74 (15.2) 56 (11.5) 25 (5.2)
unknown 1 1 0 1
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Table 4 Multivariate analysis of risk factors for PCs in LAG
All PCs Abdominal PCs Non-abdominal PCs
OR 95% CI p OR 95% CI p OR 95% CI p
Male gender 1.75 0.93-3.29 0.082 1.70 0.91-3.17 0.099 1.57 0.86-2.89 0.15
Higher age (≥75) 1.70 0.95-3.03 0.075 1.66 0.93-2.96 0.086 1.84 1.04-3.26 0.036
Heart disease 2.36 1.17-4.76 0.017 2.40 1.20-4.82 0.013 2.31 1.15-4.64 0.019
CNS disease 2.24 1.00-5.01 0.050 2.11 0.94-4.73 0.070 1.99 0.88-4.49 0.097
Liver disease 3.25 1.18-8.91 0.022 3.10 1.13-8.47 0.028
Renal dysfunction 2.01 0.98-4.13 0.058 2.13 1.06-4.29 0.035
Restrictive pulmonary dysfunction 2.08 0.81-5.34 0.13 1.95 0.76-4.99 0.16 2.12 0.83-5.42 0.12
Anemia 0.93 0.51-1.69 0.81 1.04 0.58-1.85 0.90 1.02 0.57-1.83 0.95
Hypoalbuminemia 1.53 0.21-11.2 0.67
Regular use of steroids 2.93 0.58-14.8 0.19 4.47 1.04-19.3 0.045
Total or proximal gastrectomy 1.39 0.76-2.55 0.29 1.52 0.85-2.73 0.16 1.73 0.99-3.00 0.052
Combined resection 2.85 0.88-9.27 0.081
Extended operating time (≥300 min) 1.61 0.95-2.73 0.079 1.57 0.93-2.64 0.093 1.71 1.02-2.86 0.043
Higher operative bleeding (≥500 g) 1.10 0.48-2.52 0.83 1.22 0.54-2.76 0.64
PCs postoperative complications, LAG laparoscopy-assisted gastrectomy.
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tomy in our study, because the Japanese guidelines recom-
mend LAG for the treatment of early GC. Therefore, our
results would most likely differ somewhat from those of
similar studies performed in Western countries owing to
differences in the most common sites of GC and the dis-
ease stage at diagnosis as compared with Japan.
In previous studies of only LAG in patients with mainly
early gastric cancer, higher age (≥60 years), male gender
of the patient, and type of resection or reconstruction
procedure were predictors of local PCs, and inadequateTable 5 Relationship between severity of each comorbidity
and PCs
Comorbidity Classification by severity PCs
n n (%) p
Heart disease surgical or interventional 19 5 (26) 0.26
only medication 31 13 (42)
COPD stage 3 or 4* 8 0 (0) 0.60
stage 1 or 2 104 17 (16)
CNS disease paralysis 8 2 (25) 0.69
no paralysis 31 11 (35)
Liver disease cirrhosis 8 5 (63) 0.16
hepatitis 13 3 (23)
Renal dysfunction dialysis 5 2 (40) 0.65
no dialysis 49 15 (31)
Diabetes mellitus regular use of insulin 16 4 (25) 0.46
oral medication 51 8 (16)
*The stage of COPD is defined by Global Initiative for Chronic Obstructive
Lung Disease.experience of the operator was a predictor of systemic
PCs [3,4]. Higher age was not a significant predictor of
PCs in other studies of LAG [10-13], while higher age
was significantly associated with non-abdominal PCs in
this study. In the present study, 4 surgeons qualified in
LAG performed all LAG procedures. The experience of
the surgeons thus did not affect clinical outcomes. Our
study had several limitations. Most important, it was a
single-center study performed by experts in LAG. Our
results thus might not be applicable to general hospitals.
A pooled analysis or a multicenter study involving sur-
geons with various degrees of experience is necessary to
identify common risk factors for gastrectomy.
In three studies of D2 LND including many patients
who underwent OG, multiple-organ resection, advanced
disease stage, extended operating time (≥180 or 200 mi-
nutes), higher age (≥50 years), male gender, higher BMI
(≥25), and type of reconstruction were significant inde-
pendent predictors of PCs [2,14,15]. In a randomized
clinical trial of OG with D2 or more extended LND,
higher age (>65 years), pancreatectomy, and extended
operating time (>297 minutes) were independent risk
factors for PCs [16]. In another study of open gastrectomy
with various extents of lymph-node dissection, splenec-
tomy or an extended operative time (≥360 minutes) was a
risk factor for abdominal PCs [17].
Obesity is an established operative risk factor, but
patients with a BMI of ≥30, defined as obese by the
WHO, are uncommon in Asia. Obesity has therefore
been an uncertain predictor of PCs in patients who
undergo LAG [18-21]. Diabetes mellitus is a known risk
factor for PCs after pancreaticoduodenectomy and
Table 6 Comparison between insufficient LND and
sufficient LND in patients with any risky comorbidity
Insufficient LND Sufficient LND
p
n = 42 n = 107
n (%) n (%)
Age ≥75 18 (43) 45 (42) 0.93
<75 24 (57) 62 (58)
Gender male 34 (81) 76 (71) 0.22
female 8 (19) 34 (29)
Tumor stage I 22 (52) 96 (90) <0.001
II 14 (33) 7 (7)
III 6 (14) 4 (4)
LND D1 2 (5) 1 (0.9) 0.015
D1+ 40 (95) 91 (85)
D2 0 (0) 15 (14)
No. of risky
comorbidity
1 32 (76) 83 (78) 0.73
2 9 (21) 19 (18)
≥3 1 (2) 5 (5)
All PCs 12 (29) 32 (30) 0.87
Abdominal PCs 8 (19) 27 (25) 0.42
Non-abdominal PCs 9 (21) 9 (8) 0.028
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between diabetes mellitus and PCs after gastrectomy [5].
Preoperative strict diabetic control by diabetologists for
about 2 weeks in patients with severe diabetes mellitus
in our hospital might have resulted in the favorable post-
operative course. COPD is a risk factor for postoperative
pulmonary complications after non-thoracic surgery [24].
COPD was not associated with postoperative pulmon-
ary complications in our study or in a previous study






Age <75 77.3 0.069 92.6 0.94
≥75 44.9 94.4
Gender male 76.5 0.43 100.0 0.22
female 68.5 80.8
Tumor stage I 81.8 <0.001a 100.0 <0.001a,b




1 73.3 0.19 92.8 0.61
≥2 45.1 95.0
LND sufficient 79.0 0.24 94.4 0.25
insufficient 60.6 90.6
OS; overall survival, DSS; disease-specific survival.
astage I vs III, bstage I vs II, cstage II vs III.Preoperative smoking cessation for about 3 to 4 weeks
in all patients and breathing exercises in patients with
severe COPD might have contributed to the low inci-
dence of pulmonary complications (10 patients, 1.8%),
and 8 (1.5%) patients with 3 or more severe COPDs
had no pulmonary complications in this study.
Nomograms established from preoperative data can
facilitate the design of treatment strategies, but require a
large volume of data from multiple centers. The Charlson
comorbidity index (CCI) was developed to predict 10-year
mortality for patients with a range of comorbidities [26].
Park et al. showed that the age-adjusted CCI was a useful
predictor of systemic complications after LAG [27]. E-
PASS and POSSUM predict the risks of mortality and
morbidity after various operations, and the latter has
been employed in patients undergoing gastrectomy [6,7].
However, these systems have not been routinely used in
clinical practice, and many surgeons base treatment strat-
egies on the severity of comorbidities or age of the patient.
Clinically, reduced insufficient LND is often performed in
patients with severe comorbidity or higher age, although
criteria defining the need for more conservative proce-
dures remain unclear. The indications for insufficient
LND in risky patients were decided by consensus among a
team of gastrointestinal surgeons in our hospital and were
primarily based on the general condition of risky patients;
we had no predefined criteria for such indications. We
performed at least D1+ LND in risky patients who had a
preoperative diagnosis of advanced GC. Insufficient LND
did not reduce PCs in patients with risky comorbidities. In
contrast, cardiac or pulmonary PCs increased in this
study. However, if all patients had undergone sufficient
LND, more PCs might have occurred. In addition, insuffi-
cient LND did not significantly shorten GC-specific sur-
vival in patients with any risky comorbidity. Insufficient
LND, such as D1+ LND for advanced cancer, may thus be
permissible in high-risk patients. A prospective random-
ized controlled trial would be the most reliable means of
objectively evaluating the advantages and disadvantages of
insufficient LND, but would be risky to perform in pa-
tients with severe comorbidities. A multicenter study or a
pooled analysis is considered a better means of resolving
this issue in the future. In the present study, the severity
of comorbidities was not significantly related to the inci-
dence of PCs. This finding might be attributed to the fact
that few patients with severe comorbidities were allowed
to receive prolonged general anesthesia. In such patients,
we performed local resection with limited sampling of
lymph nodes, endoscopic resection without LND, or
sometimes withheld anticancer treatments.
Conclusions
Heart, CNS, liver, renal, and pulmonary comorbidities or
dysfunctions were risk factors for PCs after LAG in
Inokuchi et al. BMC Surgery 2014, 14:97 Page 8 of 8
http://www.biomedcentral.com/1471-2482/14/97patients with GC. Heart disease and liver disease were
independent risk factors for PCs. In high-risk patients,
insufficient LND did not decrease PCs, but had no nega-
tive impact on GC-specific survival. Insufficient LND,
such as D1+ LND for advanced GC, might thus be per-
missible in this subgroup of patients.
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